Supernus Pharmaceuticals reported $55.6M in EBITDA for its fiscal quarter ending in September of 2026.





Ebitda Change Date
Abbott USD 2.43B 844M Mar/2026
ANI Pharmaceuticals USD 83.3M 11.7M Sep/2026
Aurora Cannabis CAD 799K 2.9M Jun/2026
Bristol-Myers Squibb USD 3.48B 1.6B Sep/2026
Canopy Growth CAD 8M 145M Jun/2026
Cara Therapeutics USD -2.39M 3.16M Mar/2025
Corcept Therapeutics USD 115.75M 73.59M Sep/2026
Eisai JPY 25.94B 8.21B Sep/2026
Eli Lilly USD 9.46B 3.54B Sep/2026
Novo Nordisk DKK 37.36B 2.64B Jun/2026
Pacira USD 50.45M 1.78M Sep/2026
Perrigo USD 156.6M 83M Sep/2026
Pfizer USD 6.36B 350M Sep/2026
Supernus Pharmaceuticals USD 55.6M 24M Sep/2026
United Therapeutics USD 334.2M 20.8M Sep/2026
Xeris Pharmaceuticals USD -20.94M 33.27M Jun/2026